Skip to search formSkip to main contentSkip to account menu

moexipril

Known as: 2-((1-ethoxycarbony)-3-phenylpropylamino-1-oxopropyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, Moexiprilum, moexipril [Chemical/Ingredient] 
A non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, moexipril is hydrolyzed into its active… 
National Institutes of Health

Related topics

Related topics

18 relations
AngioedemaAngiotensin-Converting Enzyme Inhibitors [MoA]Congestive heart failureDecreased Blood Pressure [PE]

Broader (3)

Angiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsTetrahydroisoquinolines

Narrower (4)

FempressMoexipril hydrochlorideRS 10085Univasc

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
The effect of combination therapy on indices of endothelial dysfunction in women with hypertension and menopausal syndrome
Aim of the study was to evaluate the efficiency of the effect of combination therapy on indices of endothelial dysfunction in… 
2006
2006
[Hypotensive, organoprotective, and metabolic effects of Angiotensin converting enzyme inhibitor moexipril in women with postmenopausal syndrome].
Hypotensive, organoprotective, and metabolic effects of angiotensin converting enzyme inhibitor moexipril (7.5-15 mg/day for 16… 
2006
2006
Comparative efficacy and safety of contemporary Angiotensin converting enzyme inhibitors moexipril and spirapril in women with postmenopausal metabolic syndrome
Moexipril (7.4-15 mg/day) was given to 34, spirapril (3-6 mg/day) -- to 18 postmenopausal women with hypertension and metabolic… 
2006
2006
[Comparative efficacy and safety of contemporary Angiotensin converting enzyme inhibitors moexipril and spirapril in women with postmenopausal metabolic syndrome].
Moexipril (7.4-15 mg/day) was given to 34, spirapril (3-6 mg/day) -- to 18 postmenopausal women with hypertension and metabolic… 
2006
2006
Моэксиприл при лечении артериальной гипертонии у женщин с остеопорозом в постменопаузе
Aim. To study effectiveness and safety of long-term monotherapy with АСГ inhibitor moexipril, as well as its combination with… 
2005
2005
The use of moexipril in postmenopausal women with hypertension and associated changes of bone mineral density
: Moexipril was given to 35 postmenopausal women with mild and moderate hypertension, menopausal syndrome and decreased bone… 
2005
2005
Moexipril influence on quality of life in postmenopausal women with arterial hypertension
AIM To evaluate a hypotensive effect and metabolic neutrality and safety of ACE inhibitor moexipril in postmenopausal women with… 
2000
2000
MODIL — wieloośrodkowe, randomizowane badanie porównujące moexipril i diltiazem w monoterapii i terapii skojarzonej nadciśnienia tętniczego
Wstep Celem badania bylo porownanie skuteczności hipotensyjnej moexiprilu i diltiazemu w monoterapii oraz terapii skojarzonej… 
1998
1998
Nutzen von Moexipril und Hydrochlorothiazid bei mäßig schwerer essentieller Hypertonie
Das Ziel dieser Studie bestand darin, die Wirksamkeit und Vertraglichkeit des Angiotensin-Konversions-Enzym-Hemmers Moexipril… 
1989
1989
An Unexpected pH Effect on the Stability of Moexipril Lyophilized Powder
Because of the limited stability of moexipril (RS-10085; 1) in aqueous solution, lyophilized parenteral formulations were… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)